Discover
ASND
Ascendis Pharma A/S
267.79
2 x 243.65
2 x 285.91
bid
ask
+
1.07
0.40%
2 @ 04:00 PM
267.79 +0.00 (0.00%)
| Ytd | 25.58% | |
| 1y | 55.69% |
262.18
day range
268.23
160.86
52 week range
271.89
| Open | 267.51 | Prev Close | 266.72 | Low | 262.18 | High | 268.23 | Mkt Cap | 17.57B |
| Vol | 516.20K | Avg Vol | 785.74K | EPS | 8.62 | P/E | 31.07 | Forward P/E | 24.86 |
| Beta | 0.48 | Short Ratio | 3.48 | Inst. Own | 110.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 233.18 | 200-d Avg | 219.94 | 1yr Est | 291.25 |
| Income Statement | |||
| Total Revenue | 246.60M | ||
| Revenues (USD) | 283.45M | ||
| Cost of Revenue | 17.52M | ||
| Gross Profit | 229.09M | ||
| Operating Expenses | 204.27M | ||
| Research and Development Expense | 59.04M | ||
| Selling, General and Administrative Expense | 145.23M | ||
| Operating Income | 24.81M | ||
| Interest Expense | 67.26M | ||
| Income Tax Expense | -677.52M | ||
| Net Income | 629.34M | ||
| Net Income Common Stock | 629.34M | ||
| Net Income Common Stock (USD) | 723.38M | ||
| Consolidated Income | 629.34M | ||
| Earnings per Basic Share | 10.20 | ||
| Earnings per Basic Share (USD) | 11.72 | ||
| Earnings per Diluted Share | 9.75 | ||
| Earning Before Interest & Taxes (EBIT) | 19.08M | ||
| Earning Before Interest & Taxes (USD) | 21.93M | ||
| Weighted Average Shares | 61.38M | ||
| Balance Sheet | |||
| Cash and Equivalents | 572.82M | ||
| Cash and Equivalents (USD) | 658.41M | ||
| Investments | 23.56M | ||
| Investments Non-Current | 23.56M | ||
| Trade and Non-Trade Receivables | 222.72M | ||
| Current Assets | 1.12B | ||
| Property, Plant & Equipment Net | 135.92M | ||
| Total Assets | 2.00B | ||
| Total Debt | 896.66M | ||
| Current Liabilities | 1.13B | ||
| Debt Non-Current | 896.66M | ||
| Total Liabilities | 1.52B | ||
| Accumulated Retained Earnings (Deficit) | 479.59M | ||
| Shareholders Equity | 487.97M | ||
| Shareholders Equity (USD) | 560.89M | ||
| Assets Non-Current | 880.94M | ||
| Total Debt (USD) | 1.03B | ||
| Deferred Revenue | 7.80M | ||
| Goodwill and Intangible Assets | 3.69M | ||
| Inventory | 314.34M | ||
| Liabilities Non-Current | 388.54M | ||
| Trade and Non-Trade Payables | 78.59M | ||
| Tax Assets | 691.66M | ||
| Tax Liabilities | 7.81M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 4.22M | ||
| Net Cash Flow from Financing | -36.83M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -51.31M | ||
| Capital Expenditure | -7.71M | ||
| Issuance (Purchase) of Equity Shares | -20.23M | ||
| Issuance (Repayment) of Debt Securities | -8.58M | ||
| Net Cash Flow from Investing | -6.75M | ||
| Net Cash Flow from Operations | -7.72M | ||
| Effect of Exchange Rate Changes on Cash | 8.09M | ||
| Share Based Compensation | 30.36M | ||